Concord Biotech reported a strong Q1 FY27 with consolidated profit after tax rising 31% year-on-year to ₹57.70 crore. Revenue also grew 26.23% to ₹257.49 crore. The company also announced the acquisition of Celliimune Biotech Private Limited, now a wholly-owned subsidiary.
Concord Biotech Reports Strong Q1 FY27 Growth, Acquires Subsidiary
Consolidated Profit after Tax: ₹57.70 crore; Consolidated Revenue: ₹257.49 crore. Reader Takeaway: Strong profit and revenue growth driven by core operations, complemented by strategic subsidiary acquisition. ## What just happened Concord Biotech Ltd. announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated profit after tax (PAT) of ₹57.70 crore, marking a significant year-on-year increase of 30.96% from ₹44.06 crore in the same quarter last fiscal. Consolidated revenue from operations also saw a healthy jump of 26.23%, reaching ₹257.49 crore compared to ₹203.99 crore in Q1 FY26. Standalone revenue was reported at ₹260.52 crore with a PAT of ₹61.19 crore. ## Why this matters The robust year-on-year growth in both revenue and profitability indicates strong operational performance and effective business strategies by Concord Biotech. The increase in PAT of over 30% suggests improved margins or higher sales volume, which are positive signs for investors. The acquisition of a new subsidiary also signals expansion and potential future revenue streams. ## The backstory Concord Biotech is a pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company has been expanding its product portfolio and market reach over the years. ## What changes now The acquisition of Celliimune Biotech Private Limited, incorporated in January 2025, as a wholly-owned subsidiary on April 2, 2026, will likely contribute to Concord Biotech's consolidated financials going forward. This move could enhance the company's service offerings and market presence in specific therapeutic areas. ## Audit and Regulatory Status The financial results for the quarter have undergone a limited review by statutory auditors BSR & Co. LLP, who provided an unmodified report. The company noted that the interim financial information of certain minor subsidiaries and a joint venture, which were not reviewed or were reviewed by other auditors, were considered immaterial to the group's overall financial statements. ## Risks to watch While the current results are positive, investors should watch for the integration and performance of the newly acquired subsidiary, Celliimune Biotech, and its contribution to the overall profitability. Any unforeseen challenges in regulatory compliance or market competition could pose risks. ## Peer comparison (Information not available in the filing. Grounded search required for peer data). ## Context metrics (time-bound) * **Q1 FY27 Consolidated Revenue:** ₹257.49 crore (up 26.23% YoY) * **Q1 FY27 Consolidated PAT:** ₹57.70 crore (up 30.96% YoY) * **Acquisition Date of Celliimune Biotech:** April 2, 2026 ## What to track next Investors will be keen to see the performance of Celliimune Biotech in subsequent quarters and its impact on Concord Biotech's consolidated financials. Continued revenue growth and profit expansion will be key indicators to monitor.
